Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O75037
UPID:
KI21B_HUMAN
Alternative names:
-
Alternative UPACC:
O75037; B2RP62; B7ZMI0; Q5T4J3
Background:
Kinesin-like protein KIF21B is a microtubule-dependent motor protein, crucial for microtubule dynamics, synapse function, and neuronal morphology. It plays a pivotal role in dendritic tree branching, spine formation, and is essential for learning and memory processes. KIF21B's processive activity is directed towards the plus-end of microtubules, facilitating the delivery of gamma-aminobutyric acid (GABA(A)) receptors to the cell surface.
Therapeutic significance:
Understanding the role of Kinesin-like protein KIF21B could open doors to potential therapeutic strategies. Its involvement in critical neurological processes highlights its potential as a target for interventions in cognitive disorders and synaptic dysfunction.